TrialAmerican journal of clinical dermatology2024

Tralokinumab Provides Clinically Meaningful Responses at Week 16 in Adults with Moderate-to-Severe Atopic Dermatitis Who Do Not Achieve IGA 0/1.

Eric L Simpson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.